Estée Lauder
No proof required
Up to $5,000
Claims opening soon
T
Teva Pharmaceuticals
Consumers and entities who purchased QVAR or QVAR Redihaler between January 1, 2015, and July 31, 2025, may be eligible for a share of this $35 million antitrust settlement.
ClosedSelected statesClaim status: Closed on July 31, 2026Payout: VariesNo longer claimable
About this settlement
Allegations that Teva engaged in antitrust practices to prevent generic competition for its QVAR asthma medication.
Teva Pharmaceuticals has agreed to a $35 million settlement to resolve claims of antitrust behavior related to its QVAR asthma medication. The settlement benefits individuals and entities who purchased or reimbursed QVAR or QVAR Redihaler within a specified period and in eligible states.
Who qualifies
- Consumers and entities who purchased or reimbursed QVAR or QVAR Redihaler.
- Purchases made between January 1, 2015, and July 31, 2025.
- Purchasers must be residents of the specified states listed in the settlement.
Varies
Claim status: Closed on July 31, 2026
Silk and Great Value
Proof required
Up to $300,000
73 days left
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
723 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon